Deal overview
| Target | TAKEDA PHARMACEUTICAL COMPANY LIMITED (XIIDRA RIGHTS) |
|---|---|
| Bidder | NOVARTIS AG |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | May 08, 2019 |
| Abstract | On 8 May 2019, the quoted Swiss pharmaceutical group Novartis AG ("Novartis") announced that it had entered into an agreement with Takeda Pharmaceutical Company Limited ("Takeda") to acquire the assets associated with the dry eye treatment Xiidra® worldwide. Takeda would receive US$ 3.4 billion upfront in cash and up to an additional US$ 1.9 billion in potential milestone ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
